NFDI4Microbiota is set to become part of Germany’s national research data infrastructure (NFDI). In May 2021, a panel of experts recommended that the consortium should receive NFDI funding – and now the Joint Science...
The Helmholtz Centre for Infection Research (HZI) has appointed PD Dr Fabian Leendertz as founding director of the Helmholtz Institute for One Health (HIOH) in Greifswald on 26 May 2021. At the same time, he accepted...
How can we apply the knowledge we have gained so far to better overcome the current crisis and prevent another pandemic in future? Helmholtz aims to find answers to these questions with two new, interdisciplinary...
Am I infected with SARS-CoV-2? Is it one of the dangerous variants? Being able to answer these and more questions with a single efficient diagnostic test can be decisive for gauging the spread of disease and selecting...
On the occasion of World Tuberculosis Day, Jennifer Herrmann, scientist in the department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), talks about the epidemiology...
After exposure to a virus through infection or vaccination, the body activates a number of cells and mechanisms that can provide targeted defense against the pathogen. For the global containment of the SARS-CoV-2...
In May 2020, the international consortium iCAIR® started a research project aimed at developing therapeutics against SARS-CoV-2. The Helmholtz Centre for Infection Research (HZI), which joined forces with the...
Every year, about 10 million people become infected with tuberculosis and 1.4 million die from it. This makes tuberculosis not only one of the most widespread infectious diseases, but also the deadliest. Similar to...
The bacterium Pseudomonas aeruginosa is among the most common causes of pneumonia and poses a major challenge to hospitals worldwide. The treatment of infections with Pseudomonas aeruginosa is usually challenging...
